Trendy anti-aging biotech Unity adds $55M as it preps first human trial to flush senescent cells

Unity Biotechnology is filling up its cash reserves with another venture round before it goes into its first anti-aging human studies. The Bay Area biotech bagged a $116 million celebrity round in 2016, with Jeff Bezos and others joining the syndicate for the Arch-seeded company, launched with Bob Nelsen's help.

About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website,

View all posts by Robert Zinn →